Cargando…

Hypofractionated Radiotherapy and Stereotactic Boost with Concurrent and Adjuvant Temozolamide for Glioblastoma in Good Performance Status Elderly Patients – Early Results of a Phase II Trial

Glioblastoma Multiforme (GBM) is an aggressive primary brain neoplasm with dismal prognosis. Based on successful phase III trials, 60 Gy involved-field radiotherapy in 30 fractions over 6 weeks [Standard radiation therapy (RT)] with concurrent and adjuvant temozolomide is currently the standard of c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Floyd, Scott R., Kasper, Ekkehard M., Uhlmann, Erik J., Fonkem, Ekokobe, Wong, Eric T., Mahadevan, Anand
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2012
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472503/ https://www.ncbi.nlm.nih.gov/pubmed/23087896 http://dx.doi.org/10.3389/fonc.2012.00122

Ejemplares similares

Stereotactic radiosurgery for brain metastasis from gynecological malignancies
por: Kasper, Ekkehard, et al.
Publicado: (2017)

Cost-Effectiveness of Temozolamide for Treatment of Glioblastoma Multiforme in India
por: Gupta, Nidhi, et al.
Publicado: (2021)

Poor-Prognosis Patients Affected by Glioblastoma: Retrospective Study of Hypofractionated Radiotherapy with Simultaneous Integrated Boost and Concurrent/Adjuvant Temozolomide
por: Gregucci, Fabiana, et al.
Publicado: (2021)

Comparison of the outcomes following bevacizumab and/or temozolamide/radiosurgery treatment in patients with glioblastoma
por: Aravantinou-Fatorou, Aikaterini, et al.
Publicado: (2023)

Stereotactic Radiosurgery for Renal Cancer Brain Metastasis: Prognostic Factors and the Role of Whole-Brain Radiation and Surgical Resection
por: Ippen, Franziska M., et al.
Publicado: (2015)

Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer
por: Anwar, Mekhail, et al.
Publicado: (2016)

Stereotactic radiosurgery for brain metastases from malignant melanoma
por: Christ, Sebastian M., et al.
Publicado: (2015)

Feasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases
por: Kornhuber, Christine, et al.
Publicado: (2023)

Therapeutic Potential of Adjuvant Stereotactic Body Radiotherapy for Gallbladder Cancer
por: Mahadevan, Anand, et al.
Publicado: (2015)

Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme
por: Jastaniyah, Noha, et al.
Publicado: (2013)

Accelerated Hypofractionated Radiotherapy in the Era of Concurrent Temozolomide Chemotherapy in Elderly Patients with Glioblastoma Multiforme
por: Greer, Liana, et al.
Publicado: (2017)

Hypofractionated stereotactic radiotherapy for large arteriovenous malformations
por: Wang, Huan-Chih, et al.
Publicado: (2012)

Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience
por: Ciammella, Patrizia, et al.
Publicado: (2013)

Clinical Outcomes of Moderately Hypofractionated Concurrent Chemoradiotherapy for Newly Diagnosed Glioblastoma
por: Kim, Nalee, et al.
Publicado: (2023)

Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment
por: Lee, Dong Soo, et al.
Publicado: (2012)

Phase 1 study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas
por: Newlands, E S, et al.
Publicado: (2003)

Safety and Efficacy of Hypofractionated Stereotactic Radiotherapy with Anlotinib Targeted Therapy for Glioblastoma at the First Recurrence: A Preliminary Report
por: Guan, Yun, et al.
Publicado: (2022)

Diffusion weighted MRI as an early predictor of tumor response to hypofractionated stereotactic boost for prostate cancer
por: Pasquier, David, et al.
Publicado: (2018)

Estimating the tolerance of brachial plexus to hypofractionated stereotactic body radiotherapy: a modelling-based approach from clinical experience
por: Kapitanova, Irina, et al.
Publicado: (2021)

The Judicious Use of Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy in the Management of Large Brain Metastases
por: Gutschenritter, Tyler, et al.
Publicado: (2020)

Dosimetric Comparison of Upfront Boosting With Stereotactic Radiosurgery Versus Intraoperative Radiotherapy for Glioblastoma
por: Sarria, Gustavo R., et al.
Publicado: (2021)

Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules?
por: Shibamoto, Yuta, et al.
Publicado: (2016)

Intracranial chordoma: radiosurgery, hypofractionated stereotactic radiotherapy and treatment outcomes
por: Napieralska, Aleksandra, et al.
Publicado: (2021)

Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: results of a prospective trial
por: Krug, David, et al.
Publicado: (2020)

Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: A systematic literature review
por: Schmitt, Martin, et al.
Publicado: (2022)

The oxido-metabolic driver ATF4 enhances temozolamide chemo-resistance in human gliomas
por: Chen, Daishi, et al.
Publicado: (2017)

Bufalin Induces Apoptosis and Improves the Sensitivity of Human Glioma Stem-Like Cells to Temozolamide
por: Liu, Jia, et al.
Publicado: (2019)

Evaluation of efficacy and safety of robotic stereotactic body radiosurgery and hypofractionated stereotactic radiotherapy for vertebral metastases
por: Księżniak-Baran, Dorota, et al.
Publicado: (2015)

Dosimetric analysis of the alopecia preventing effect of hippocampus sparing whole brain radiation therapy
por: Mahadevan, Anand, et al.
Publicado: (2015)

Efficacy and Safety of Primary Stereotactic Radiosurgery in Patients With Intraventricular Meningiomas
por: Christ, Sebastian M., et al.
Publicado: (2022)

Concurrent Hypofractionated Radiotherapy and 5-Fluorouracil for Advanced Sarcomas of the Bone
por: Zambatis, Charalambos, et al.
Publicado: (1998)

Reproducibility and geometric accuracy of the fixster system during hypofractionated stereotactic radiotherapy
por: Lindvall, Peter, et al.
Publicado: (2008)

Hypofractionated stereotactic radiotherapy for brain metastases larger than three centimeters
por: Jiang, Xue-song, et al.
Publicado: (2012)

Cone-beam computed tomography in hypofractionated stereotactic radiotherapy for brain metastases
por: Ingrosso, Gianluca, et al.
Publicado: (2012)

Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma
por: Kim, Hun Jung, et al.
Publicado: (2016)

Adjuvant treatment of meningioma with stereotactic radiation surgery and hypofractionated stereotactic radiation surgery: Patterns of care and survival in a large, hospital database
por: Albert, Ashley, et al.
Publicado: (2018)

CLRM-02 SINGLE CENTER EXPERIENCE OF DOPAMINE ANTAGONIST ONC-201 FOR RECURRENT H3K27M-MUTANT GLIOBLASTOMA IN ADULTS
por: Ekhator, Chukwuyem, et al.
Publicado: (2022)

Long-Term Results of Postoperative Hypofractionated Accelerated Breast and Lymph Node Radiotherapy (HypoAR) with Hypofractionated Boost
por: Koukourakis, Ioannis M., et al.
Publicado: (2021)

Hypofractionated Stereotactic Radiotherapy for Patients with Intracranial Meningiomas: impact of radiotherapy regimen on local control
por: Meniai-Merzouki, F., et al.
Publicado: (2018)

Hypofractionated stereotactic radiotherapy for large or involving critical organs cerebral arteriovenous malformations
por: Blamek, Sławomir, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_i0hvhqfll04kv2nam27do645la